KRAS突变-话题@MedSci

#KRAS突变#

32篇内容 | 2701人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=1332868, encodeId=08bc1332868a5, content=<a href='/topic/show?id=e070105e2bb' target=_blank style='color:#2F92EE;'>#KRAS突变#</a>, objectTitle=KRAS突变靶向药物AMG510即将进入中国开展临床试验, objectType=article, longId=191150, objectId=311c19115003, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=311c19115003, replyNumber=0, likeNumber=100, createdTime=2020-04-01, rootId=0, userName=ms5906905816781247, userId=9d712500079, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=311c19115003, moduleTitle=KRAS突变靶向药物AMG510即将进入中国开展临床试验, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=311c19115003)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1332867, encodeId=e0e6133286e17, content=<a href='/topic/show?id=e070105e2bb' target=_blank style='color:#2F92EE;'>#KRAS突变#</a>, objectTitle=PLK1抑制剂Onvasertib治疗KRAS突变的mCRC患者：肿瘤消退和临床获益, objectType=article, longId=186925, objectId=3f7618692587, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=3f7618692587, replyNumber=0, likeNumber=104, createdTime=2020-01-30, rootId=0, userName=ms5906905816781247, userId=9d712500079, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=3f7618692587, moduleTitle=PLK1抑制剂Onvasertib治疗KRAS突变的mCRC患者：肿瘤消退和临床获益, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=3f7618692587)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1332866, encodeId=7290133286629, content=<a href='/topic/show?id=e070105e2bb' target=_blank style='color:#2F92EE;'>#KRAS突变#</a>, objectTitle=Modern Pathology：反极性乳头状肾细胞癌中鉴定了复发性KRAS突变, objectType=article, longId=186807, objectId=d11a18680eac, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=d11a18680eac, replyNumber=0, likeNumber=0, createdTime=2020-01-29, rootId=0, userName=ms5906905816781247, userId=9d712500079, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=d11a18680eac, moduleTitle=Modern Pathology：反极性乳头状肾细胞癌中鉴定了复发性KRAS突变, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=d11a18680eac)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1332865, encodeId=406f133286514, content=<a href='/topic/show?id=e070105e2bb' target=_blank style='color:#2F92EE;'>#KRAS突变#</a>, objectTitle=Clinica Chimica Acta：利用改进的野生型阻断剂可在单管中敏感、选择性地检测密码子12和13 KRAS突变, objectType=article, longId=179432, objectId=0a3e1e94321f, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=0a3e1e94321f, replyNumber=0, likeNumber=100, createdTime=2019-09-15, rootId=0, userName=ms5906905816781247, userId=9d712500079, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=0a3e1e94321f, moduleTitle=Clinica Chimica Acta：利用改进的野生型阻断剂可在单管中敏感、选择性地检测密码子12和13 KRAS突变, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=0a3e1e94321f)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1332864, encodeId=644413328641f, content=<a href='/topic/show?id=e070105e2bb' target=_blank style='color:#2F92EE;'>#KRAS突变#</a>, objectTitle=针对KRAS突变驱动的癌症疫苗, objectType=article, longId=177310, objectId=f1711e73100d, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=f1711e73100d, replyNumber=0, likeNumber=99, createdTime=2019-08-10, rootId=0, userName=ms5906905816781247, userId=9d712500079, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=f1711e73100d, moduleTitle=针对KRAS突变驱动的癌症疫苗, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=f1711e73100d)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1332863, encodeId=03e0133286364, content=<a href='/topic/show?id=e070105e2bb' target=_blank style='color:#2F92EE;'>#KRAS突变#</a>, objectTitle=Amgen的AMG 510在KRAS突变的非小细胞肺癌I期临床实现突破, objectType=article, longId=167693, objectId=bf9916e693b0, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=bf9916e693b0, replyNumber=0, likeNumber=99, createdTime=2019-06-06, rootId=0, userName=ms5906905816781247, userId=9d712500079, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=bf9916e693b0, moduleTitle=Amgen的AMG 510在KRAS突变的非小细胞肺癌I期临床实现突破, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=bf9916e693b0)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1332862, encodeId=0b3b133286231, content=<a href='/topic/show?id=e070105e2bb' target=_blank style='color:#2F92EE;'>#KRAS突变#</a>, objectTitle=Cell Metab:糖真的有毒！高血糖环境下，胰腺细胞中致癌的KRAS突变暴增，或为导致胰腺癌的罪魁祸首之一, objectType=article, longId=163057, objectId=c6f416305ec3, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=c6f416305ec3, replyNumber=0, likeNumber=79, createdTime=2019-03-28, rootId=0, userName=ms5906905816781247, userId=9d712500079, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=c6f416305ec3, moduleTitle=Cell Metab:糖真的有毒！高血糖环境下，胰腺细胞中致癌的KRAS突变暴增，或为导致胰腺癌的罪魁祸首之一, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=c6f416305ec3)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1332861, encodeId=51251332861b1, content=<a href='/topic/show?id=e070105e2bb' target=_blank style='color:#2F92EE;'>#KRAS突变#</a>, objectTitle=Sci Transl Med:KRAS突变型肺癌或喜迎MEK抑制剂联合用药, objectType=article, longId=162939, objectId=156a1629396a, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=156a1629396a, replyNumber=0, likeNumber=82, createdTime=2019-03-26, rootId=0, userName=ms5906905816781247, userId=9d712500079, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=156a1629396a, moduleTitle=Sci Transl Med:KRAS突变型肺癌或喜迎MEK抑制剂联合用药, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=156a1629396a)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1332860, encodeId=f7cd133286072, content=<a href='/topic/show?id=e070105e2bb' target=_blank style='color:#2F92EE;'>#KRAS突变#</a>, objectTitle=JTO：病例分享——见微知著，KRAS突变肺腺癌转化为小细胞肺癌是免疫治疗的耐药机制？, objectType=article, longId=159865, objectId=7f2d1598656e, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=7f2d1598656e, replyNumber=0, likeNumber=92, createdTime=2019-02-14, rootId=0, userName=ms5906905816781247, userId=9d712500079, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=7f2d1598656e, moduleTitle=JTO：病例分享——见微知著，KRAS突变肺腺癌转化为小细胞肺癌是免疫治疗的耐药机制？, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=7f2d1598656e)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1332859, encodeId=89b5133285953, content=<a href='/topic/show?id=e070105e2bb' target=_blank style='color:#2F92EE;'>#KRAS突变#</a>, objectTitle=ARCH PATHOL LAB MED：肺癌，结直肠癌和胰腺癌组织和血浆中KRAS突变检测的方法, objectType=article, longId=159572, objectId=4fbc1595e2df, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=4fbc1595e2df, replyNumber=0, likeNumber=71, createdTime=2019-02-08, rootId=0, userName=ms5906905816781247, userId=9d712500079, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=4fbc1595e2df, moduleTitle=ARCH PATHOL LAB MED：肺癌，结直肠癌和胰腺癌组织和血浆中KRAS突变检测的方法, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=4fbc1595e2df)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1332858, encodeId=2ca41332858d3, content=<a href='/topic/show?id=e070105e2bb' target=_blank style='color:#2F92EE;'>#KRAS突变#</a>, objectTitle=Oncogene：Kras突变能够诱导的CD24表达上调能够增强前列腺癌的多能性和骨转移, objectType=article, longId=156369, objectId=cc76156369d4, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=cc76156369d4, replyNumber=0, likeNumber=81, createdTime=2018-12-23, rootId=0, userName=ms5906905816781247, userId=9d712500079, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=cc76156369d4, moduleTitle=Oncogene：Kras突变能够诱导的CD24表达上调能够增强前列腺癌的多能性和骨转移, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=cc76156369d4)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1332857, encodeId=8435133285e70, content=<a href='/topic/show?id=e070105e2bb' target=_blank style='color:#2F92EE;'>#KRAS突变#</a>, objectTitle=CLIN CHEM：多重检测胰腺导管腺癌患者游离DNA 中KRAS突变的预后意义, objectType=article, longId=134277, objectId=24ab1342e7a2, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=24ab1342e7a2, replyNumber=0, likeNumber=70, createdTime=2018-04-06, rootId=0, userName=ms5906905816781247, userId=9d712500079, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=24ab1342e7a2, moduleTitle=CLIN CHEM：多重检测胰腺导管腺癌患者游离DNA 中KRAS突变的预后意义, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=24ab1342e7a2)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1332856, encodeId=c429133285654, content=<a href='/topic/show?id=e070105e2bb' target=_blank style='color:#2F92EE;'>#KRAS突变#</a>, objectTitle=EUR J Cancer：放疗联合卡培他滨和索拉非尼治疗晚期KRAS突变的直肠癌：I / II期临床试验（SAKK 41/08）, objectType=article, longId=124481, objectId=c81c12448125, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=c81c12448125, replyNumber=0, likeNumber=62, createdTime=2017-12-26, rootId=0, userName=ms5906905816781247, userId=9d712500079, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=c81c12448125, moduleTitle=EUR J Cancer：放疗联合卡培他滨和索拉非尼治疗晚期KRAS突变的直肠癌：I / II期临床试验（SAKK 41/08）, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=c81c12448125)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1332855, encodeId=7ba61332855f4, content=<a href='/topic/show?id=e070105e2bb' target=_blank style='color:#2F92EE;'>#KRAS突变#</a>, objectTitle=CLIN CANCER RES：WEE1和mTOR协同抑制治疗KRAS突变肺癌, objectType=article, longId=121369, objectId=ea411213694d, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=ea411213694d, replyNumber=0, likeNumber=69, createdTime=2017-11-27, rootId=0, userName=ms5906905816781247, userId=9d712500079, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=ea411213694d, moduleTitle=CLIN CANCER RES：WEE1和mTOR协同抑制治疗KRAS突变肺癌, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=ea411213694d)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1332854, encodeId=4f68133285492, content=<a href='/topic/show?id=e070105e2bb' target=_blank style='color:#2F92EE;'>#KRAS突变#</a>, objectTitle=ANN SURG：解剖性切除可以改善KRAS突变结直肠癌肝转移患者无病生存, objectType=article, longId=114633, objectId=757411463395, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=757411463395, replyNumber=0, likeNumber=78, createdTime=2017-09-30, rootId=0, userName=ms5906905816781247, userId=9d712500079, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=757411463395, moduleTitle=ANN SURG：解剖性切除可以改善KRAS突变结直肠癌肝转移患者无病生存, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=757411463395)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1332853, encodeId=34a0133285365, content=<a href='/topic/show?id=e070105e2bb' target=_blank style='color:#2F92EE;'>#KRAS突变#</a>, objectTitle=Sci Rep：不同类型胰腺癌细胞中KRAS突变的异质性, objectType=article, longId=110587, objectId=940911058e28, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=940911058e28, replyNumber=0, likeNumber=78, createdTime=2017-08-24, rootId=0, userName=ms5906905816781247, userId=9d712500079, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=940911058e28, moduleTitle=Sci Rep：不同类型胰腺癌细胞中KRAS突变的异质性, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=940911058e28)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1332852, encodeId=30441332852f0, content=<a href='/topic/show?id=e070105e2bb' target=_blank style='color:#2F92EE;'>#KRAS突变#</a>, objectTitle=CLIN CANCER RES：肺癌TP53及KRAS突变预测阻断PD-1免疫治疗反应, objectType=article, longId=104354, objectId=cb2b10435459, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=cb2b10435459, replyNumber=0, likeNumber=59, createdTime=2017-07-04, rootId=0, userName=ms5906905816781247, userId=9d712500079, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=cb2b10435459, moduleTitle=CLIN CANCER RES：肺癌TP53及KRAS突变预测阻断PD-1免疫治疗反应, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=cb2b10435459)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1332851, encodeId=dd6f13328511d, content=<a href='/topic/show?id=e070105e2bb' target=_blank style='color:#2F92EE;'>#KRAS突变#</a>, objectTitle=Ann Oncol：MEK抑制剂trametinib对KRAS突变的非小细胞肺癌的II期临床研究, objectType=article, longId=47689, objectId=936f4e689f6, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=936f4e689f6, replyNumber=0, likeNumber=44, createdTime=2015-03-05, rootId=0, userName=ms5906905816781247, userId=9d712500079, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=936f4e689f6, moduleTitle=Ann Oncol：MEK抑制剂trametinib对KRAS突变的非小细胞肺癌的II期临床研究, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=936f4e689f6)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1332850, encodeId=da0e133285070, content=<a href='/topic/show?id=e070105e2bb' target=_blank style='color:#2F92EE;'>#KRAS突变#</a>, objectTitle=Cancer：基因KRAS突变与晚期肺腺癌患者更短存活相关联, objectType=article, longId=8408, objectId=3968840823, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=3968840823, replyNumber=0, likeNumber=69, createdTime=2012-08-02, rootId=0, userName=ms5906905816781247, userId=9d712500079, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=3968840823, moduleTitle=Cancer：基因KRAS突变与晚期肺腺癌患者更短存活相关联, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=3968840823)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1332849, encodeId=ddae133284927, content=<a href='/topic/show?id=e070105e2bb' target=_blank style='color:#2F92EE;'>#KRAS突变#</a>, objectTitle=Br J Cancer: HRMA识别KRAS突变优于直接测序, objectType=article, longId=8095, objectId=85ef80953c, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=85ef80953c, replyNumber=0, likeNumber=65, createdTime=2012-07-25, rootId=0, userName=ms5906905816781247, userId=9d712500079, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=85ef80953c, moduleTitle=Br J Cancer: HRMA识别KRAS突变优于直接测序, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=85ef80953c)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] 梅斯话题小助手

KRAS突变

2020-05-29

ms5906905816781247 (审核中...)

前往app查看评论内容

#KRAS突变#

KRAS突变靶向药物AMG510即将进入中国开展临床试验

2020-04-01

ms5906905816781247 (审核中...)

前往app查看评论内容

#KRAS突变#

PLK1抑制剂Onvasertib治疗KRAS突变的mCRC患者：肿瘤消退和临床获益

2020-01-30

ms5906905816781247 (审核中...)

前往app查看评论内容

#KRAS突变#

Modern Pathology：反极性乳头状肾细胞癌中鉴定了复发性KRAS突变

2020-01-29

ms5906905816781247 (审核中...)

前往app查看评论内容

#KRAS突变#

Clinica Chimica Acta：利用改进的野生型阻断剂可在单管中敏感、选择性地检测密码子12和13 KRAS突变

2019-09-15

ms5906905816781247 (审核中...)

前往app查看评论内容

#KRAS突变#

针对KRAS突变驱动的癌症疫苗

2019-08-10

ms5906905816781247 (审核中...)

前往app查看评论内容

#KRAS突变#

Amgen的AMG 510在KRAS突变的非小细胞肺癌I期临床实现突破

2019-06-06

ms5906905816781247 (审核中...)

前往app查看评论内容

#KRAS突变#

Cell Metab:糖真的有毒！高血糖环境下，胰腺细胞中致癌的KRAS突变暴增，或为导致胰腺癌的罪魁祸首之一

2019-03-28

ms5906905816781247 (审核中...)

前往app查看评论内容

#KRAS突变#

Sci Transl Med:KRAS突变型肺癌或喜迎MEK抑制剂联合用药

2019-03-26

ms5906905816781247 (审核中...)

前往app查看评论内容

#KRAS突变#

JTO：病例分享——见微知著，KRAS突变肺腺癌转化为小细胞肺癌是免疫治疗的耐药机制？

2019-02-14

ms5906905816781247 (审核中...)

前往app查看评论内容

#KRAS突变#

ARCH PATHOL LAB MED：肺癌，结直肠癌和胰腺癌组织和血浆中KRAS突变检测的方法

2019-02-08

ms5906905816781247 (审核中...)

前往app查看评论内容

#KRAS突变#

Oncogene：Kras突变能够诱导的CD24表达上调能够增强前列腺癌的多能性和骨转移

2018-12-23

ms5906905816781247 (审核中...)

前往app查看评论内容

#KRAS突变#

CLIN CHEM：多重检测胰腺导管腺癌患者游离DNA 中KRAS突变的预后意义

2018-04-06

ms5906905816781247 (审核中...)

前往app查看评论内容

#KRAS突变#

EUR J Cancer：放疗联合卡培他滨和索拉非尼治疗晚期KRAS突变的直肠癌：I / II期临床试验（SAKK 41/08）

2017-12-26

ms5906905816781247 (审核中...)

前往app查看评论内容

#KRAS突变#

CLIN CANCER RES：WEE1和mTOR协同抑制治疗KRAS突变肺癌

2017-11-27

ms5906905816781247 (审核中...)

前往app查看评论内容

#KRAS突变#

ANN SURG：解剖性切除可以改善KRAS突变结直肠癌肝转移患者无病生存

2017-09-30

ms5906905816781247 (审核中...)

前往app查看评论内容

#KRAS突变#

Sci Rep：不同类型胰腺癌细胞中KRAS突变的异质性

2017-08-24

ms5906905816781247 (审核中...)

前往app查看评论内容

#KRAS突变#

CLIN CANCER RES：肺癌TP53及KRAS突变预测阻断PD-1免疫治疗反应

2017-07-04

ms5906905816781247 (审核中...)

前往app查看评论内容

#KRAS突变#

Ann Oncol：MEK抑制剂trametinib对KRAS突变的非小细胞肺癌的II期临床研究

2015-03-05

ms5906905816781247 (审核中...)

前往app查看评论内容

#KRAS突变#

Cancer：基因KRAS突变与晚期肺腺癌患者更短存活相关联

2012-08-02

ms5906905816781247 (审核中...)

前往app查看评论内容

#KRAS突变#

Br J Cancer: HRMA识别KRAS突变优于直接测序

2012-07-25

科室
- - 订阅+
  - 更多科室
工具
服务